





# **Methylation profiling report**

Sample identifier: sampleName1573983851

Sentrix ID: 203057710034\_R06C01

Material type: KRYO DNA

Gender: NA

Supplier diagnosis: -

**Supplier information** 

Automatic pre	diction		
Array type:		EPIC	
Material type:		KRYO DNA	<b>~</b>
Gender:		male	
Legend: ✔ OK	Supplier information or prediction not available	★Warning, missmatch of predictio and supplier information	n

### Brain tumor methylation classifier results (v11b4)


Methylation classes (MCs with score >= 0.3)	Calibrated score	Interpretatio	'n
methylation class family Plexus Tumor	0.3	no match	X
MC family members with score >= 0.1			
methylation class plexus tumor, subclass pediatric A	0.21		
Legend: ✓ Match (score >= 0.9) X No match (score < 0.9): possibly still relevant for low tumor content and low DNA quality cases. ■ Match to		MC family memb = 0.5)	er

#### **Class descriptions**

Methylation class family Plexus Tumor: The methylation class family "Plexus Tumor" comprises the methylation classes plexus tumor, pediatric subtype A, plexus tumor, pediatric subtype B and plexus tumor, adult subtype.

Methylation class plexus tumor, subclass pediatric A: The methylation class "plexus tumor, subclass pediatric A" comprises cases diagnosed as choroid plexus papillomas and atypical choroid plexus papillomas. These tumors occur preferentially supratentorial in the lateral or 3rd ventricle but also infratentorial in or around the 4th ventricle; median age is 0 years (range 0 to 9). Additional characteristic molecular features of this class are not known to date. Numeric whole chromosome changes are frequent in this class, often including gain of chromosome 5, 8, 9, 11, 12, 14, 15, 20 and X (each in over 40% of cases).


# Copy number variation profile



Depiction of chromosome 1 to 22 (and X/Y if automatic prediction was successful). Gains/amplifications represent positive, losses negative deviations from the baseline. 29 brain tumor relevant gene regions are highlighted for easier assessment. (see Hovestadt & Zapatka, <a href="http://www.bioconductor.org/packages/devel/bioc/html/conumee.html">http://www.bioconductor.org/packages/devel/bioc/html/conumee.html</a>)

# MGMT promotor methylation (MGMT-STP27)

MGMT promotor status prediction



(see Bady et al, J Mol Diagn 2016; 18(3):350-61)

# **Disclaimer**

Classification using methylation profiling is a research tool under development, it is not verified and has not been clinically validated. Implementation of the results in a clinical setting is in the sole responsibility of the treating physician. Intended for non-commercial use only.

#### **Run information**

Report: idat\_reportBrain\_v11b4\_sample Version 2.0 Task version:

Task	Version
idat_qc	2.0
idat_predictBrain	2.1
idat_rs_gender	2.0
idat_predictMGMT	2.0
idat_cnvp	3.0
idat_reportBrain_v11b4	2.0